GamingStock Market
The Witcher 3 Remastered Is Free; CD Projekt Shares Slip 0.8% on Heavy Volume
The Witcher 3: Wild Hunt — Remastered gives CD Projekt S.A. a low-price acquisition tool for its 2027 paid expansion. The upgrade is free…
Market intelligence
Mateusz Kaczmarek
All coverage
Mateusz Kaczmarek
WSE: CDR · Product catalyst
The Witcher 3: Wild Hunt — Remastered
A free September upgrade expands the funnel for a paid 2027 expansion.
Market snapshot
Aug. 26, 2026 · 15:23:28 CEST
Aug. 26, 2026 · 15:23:28 CEST
Share price
240.90 zł
−0.82% · −2.00 zł
Range 240.00–246.70 zł
Trading activity
395.85K
1.39× average daily volume
Average: 285.26K shares
Installed base
65M+
Lifetime Witcher 3 copies sold
Analyst case
70–75M
Potential base before 2027 expansion
From free upgrade to paid-content revenue
Sept. 29
Free remaster
Free remaster
→
New reach
Switch 2 + Battle.net
Switch 2 + Battle.net
→
2027
Paid Songs of the Past
Paid Songs of the Past
Launch facts
Gamescom reveal and trailer.
Original expansions become free for existing owners.
Remaster launches; new native Switch 2 and Battle.net editions.
Paid Songs of the Past expansion.
Q1 2026 economics
| Metric | Value | YoY |
|---|---|---|
| Group revenue | 191.1M zł | +6% |
| Witcher IP revenue | 44.7M zł | +36% |
| Witcher share of sales | 23.4% | +5.2 pts |
| Net profit | 106.2M zł | −5% |
| Cash/deposits/bonds | 1.41B zł | +6% q/q |
Stock and valuation
| Signal | Reading |
|---|---|
| Market cap | 24.01B zł |
| Quoted value lost today | ≈199.8M zł |
| Trailing P/E | 39.41× |
| 52-week range | 211.30–297.00 zł |
| Shares outstanding | 99.91M |
| Erste view | Meaningful positive Q4 impact |
Investor interpretation
| Driver | Upside | Constraint |
|---|---|---|
| Free remaster | Reactivates a 65M-player catalogue | No upgrade revenue from existing owners |
| New platforms | Incremental unit sales and distribution | Platform royalties and launch costs |
| Paid 2027 expansion | Monetizes a larger installed base | Pricing and release date undisclosed |
| 2028 Witcher 4 target | Extends franchise roadmap | Long flagship-release gap |
Risk check
The 70–75 million-copy figure is an analyst estimate. A free update can lift engagement without converting into enough new purchases or expansion sales.
Attention signal
Google Trend: “the witcher 3 wild hunt remastered” · Canada, active at selection; trading volume already above average.
Sources: CD Projekt announcement and Q1 2026 presentation; Reuters, Aug. 26, 2026; Google Finance at 15:23:28 CEST. Time-sensitive figures are timestamped above.
EarningsSemiconductors
Photronics Shares Surge 23% Premarket as Share of High-End IC Mask Mix Reaches All-Time High of 44%
BROOKFIELD, Connecticut, August 26, 2026, 09:20 - Photronics stock rose 23% in premarket trading after the company reported that high-end IC mask mix soared…
Photronics investor dashboard
NASDAQ:PLAB · Premarket snapshot: August 26, 2026, 09:18 EDT
Premarket price
$36.12
+$6.80 · +23.19%
Implied value added
$400.9m
58.96m shares outstanding
Revenue / estimate
$216.0m
+3.5% beat
Adjusted EPS / estimate
$0.50
+24.0% beat
Quarterly revenue mix
IC photomasksFPD photomasksUSD millions
Why the market is paying attention
High-end IC mix reached a record 44% of IC revenue. That implies about $68.1m of quarterly high-end IC sales, or 31.5% of company revenue.
The $400.9m premarket value gain equals 5.9 times this estimated quarterly revenue stream. It prices a richer mix, not just a modest top-line beat.
Margin confirmation matters: Q3 gross margin recovered to 33.2%, but remained below the 33.7% level one year earlier.
Operating scorecard
| Metric | Q3 FY26 | Q2 FY26 | Q3 FY25 | Signal |
|---|---|---|---|---|
| Revenue | $216.0m | $209.9m | $210.4m | Improving |
| IC revenue | $154.7m | $147.5m | $147.8m | +5% both ways |
| FPD revenue | $61.4m | $62.4m | $62.6m | -2% both ways |
| Adjusted EPS | $0.50 | $0.42 | $0.51 | Sequential rebound |
| Gross margin | 33.2% | 31.3% | 33.7% | +190 bp q/q |
| Operating margin | 21.1% | 20.1% | 22.9% | Below year ago |
Q4 FY2026 guide versus consensus
Revenue
$207m–$227m
Midpoint $217m vs. $215.7m consensus
Adjusted EPS
$0.40–$0.56
Midpoint $0.48 vs. $0.42 consensus
Operating-margin guidance: 19%–24%; midpoint 21.5% versus Q3’s 21.1%.
Liquidity and valuation
| Implied premarket market cap | $2.13bn |
| Cash + short-term investments | $672.8m |
| JV-associated portion | $503.5m |
| Q3 operating cash flow | $76.3m |
| Q3 capex | $37.0m |
| Analyst average target | $46.00 |
The $46 target implies about 27% upside from $36.12. Three tracked analysts rate the shares Buy; coverage is limited.
Catalysts and risks
What can extend the move
- Volume confirms the premarket revaluation.
- High-end IC mix stays near the 44% record.
- Q4 revenue and margin land above their midpoints.
- U.S. and Korea capacity investments remain on schedule.
What can break the thesis
- Premarket liquidity exaggerates the opening move.
- FPD weakness spreads into another quarter.
- Customer design releases slip again.
- Joint-venture cash is less accessible than headline liquidity suggests.
EarningsStock Market
Woolworths Stock Gains 3.4% as Ooshies Boost Early Food Sales by Up to 2 Points
Shares of Woolworths Group Limited climbed 3.42% on Wednesday. The retailer reported that Disney Ooshies contributed as many as two percentage points to early…
ASX:WOW · FY2026 result
Woolworths reprices the recovery after a promotion-led sales lift
Market closedAugust 26, 2026 · 16:00 AEST
Share move
A$40.18+3.42%
+A$1.33
+A$1.33
Estimated market value: A$49.0bn · Estimated value added: A$1.62bn
Low A$39.90Close A$40.18High A$41.19
Volume: 4.50m shares. Value calculations use approximately 1.22bn shares outstanding.
Why investors paid attention
Ooshies supplied 1.5–2.0 points of Woolworths’ 7.6% early FY2027 Australian Food sales growth.
That equals 19.7%–26.3% of the reported growth rate. The campaign ended August 25, making sales retention the next test.
- FY2026 EBIT increaseabout A$351m
- One-day equity-value gain / EBIT increaseabout 4.6×
- Australian Food margin5.5% vs 5.3%
FY2026 financial signals
Group salesA$71.539bn+3.6%
EBIT before significant itemsA$3.105bn+12.7%
Underlying NPATA$1.599bn+15.4%
Australian Food salesA$53.852bn+4.6%
E-commerce salesA$10.596bn+15.9%
Full-year dividendA$0.97+15.5%
Growth mix and peer check
WOWOoshies contributionColes
Analyst expectations
Average targetA$37.047.8% below close
3 Buy7 Hold5 Sell
Target range: A$31.50–A$40.90. The high target is only 1.8% above the close.
Risks
- Promotion roll-offOoshies ended Aug. 25
- Price investment1,035 Lower Shelf Price products
- Average reduction16.4%
- Cost pressureWages can absorb margin gains
What changes the thesis
- PositiveFood growth holds above Coles after Ooshies
- Positive5.5% food margin proves durable
- NegativeGrowth falls by the full 1.5–2.0 points
- Valuation checkConsensus target remains below market
ASX:WTCEarnings
WiseTech Shares Slide 9.6% Following 6%-10% Revenue Guidance Despite Record Sales
Shares in WiseTech Global Limited dropped 9.6% on Wednesday. The company finished at A$41.10, after reaching as low as A$40.80 during the session, market…
ASX:WTC · Company · Stock move
Growth slowed. The valuation reset.
Market data: 26 Aug 2026, 16:12 AEST
Financials: FY ended 30 Jun 2026
Financials: FY ended 30 Jun 2026
CloseA$41.10−9.6% · A$4.37
Quoted value erasedA$1.46bn333.43m shares × A$4.37
FY26 revenueUS$1.396bn+79% year on year
FY27 revenue guideUS$1.48–1.54bn+6% to +10%
The earnings bridge
| US$ million | FY25 | FY26 | FY27 guide |
|---|---|---|---|
| Revenue | 778.7 | 1,395.9 | 1,480–1,540 |
| Underlying EBITDA | 413.9 | 644.5 | 725–780 |
| Underlying margin | 53% | 46% | 49%–51% |
| Statutory NPAT | 200.7 | 178.7 | — |
What drove attention
- e2open: US$541.2m of revenue from 11 months of consolidation.
- CargoWise: US$756.9m revenue, up 11%.
- Cash: US$489.6m underlying free cash flow, up 67%.
- Leverage: 2.7× net debt/EBITDA at 30 Jun 2026.
- Efficiency: US$115m annualised run-rate savings.
Price reaction versus Tuesday's close
Analyst expectations
A$65.16Average target from 16 analysts, published before the FY26 result. Consensus: Buy. Implied upside from A$41.10: 58.5%.
11 Strong Buy2 Buy3 HoldJul 2026 snapshotWhat can break the thesis
Revenue growth must reaccelerate after e2open's first-year step-up. Freight weakness can slow transaction revenue. Integration costs, regulatory scrutiny and restructuring may delay the 49%–51% FY27 margin target.
ACCC inquiryIntegrationFreight cycleExecutionSources: WiseTech FY26 results and investor centre; ASX-market reporting; StockAnalysis S&P Global consensus. All company financials are in U.S. dollars unless stated. Market-value change is an estimate using reported shares outstanding.
Earnings ReportsNYSE:STDN
Standard Nuclear Shares Climb 15% as First Quarterly Results Approaches
Shares of Standard Nuclear Inc. surged 14.7% on Tuesday, with investors anticipating the nuclear-fuel firm's first quarterly results since its listing in July. By…
NYSE: STDN · earnings setup
Standard Nuclear: the market is pricing backlog conversion
Market snapshot
Aug. 25, 2026 · 15:10 EDT
Aug. 25, 2026 · 15:10 EDT
Share price
$13.70
+$1.76 · +14.70%
Market value
$2.20B
≈$283M added today
Volume
1.25M
1.10× three-month average
Intraday range
$12.44–$14.90
High matched 52-week peak
The valuation bridge
Tuesday's market-value gain alone equals 4.35× funded backlog and 476× first-quarter revenue. Wednesday's report must show how signed work reaches the income statement.
Funded backlog: $65MContract options: $157MContingent backlog: $23MTotal disclosed: up to $245M
Price vs. sell-side range
$16.00
Average target · 7 ratings
Low $11 · current $13.70 · high $20
Financial baseline
| Metric | Q1 2026 / Mar. 31 | Read-through |
|---|---|---|
| Revenue | $0.594M | +57% year on year |
| Cost of revenue | $5.01M | Scale not yet economic |
| Net loss | -$7.71M | Early-stage spending |
| Cash | $124.9M | Before $150M IPO |
| Funded backlog | $65M | Binding work |
Analyst recommendations
| Firm | Rating | Target |
|---|---|---|
| RBC Capital | Outperform | $11 |
| BofA Securities | Buy | $15 |
| Stifel | Buy | $16 |
| Barclays | Overweight | $17 |
| Evercore ISI | Outperform | $17 |
| Goldman Sachs | Buy | $18 |
Initiations dated Aug. 10, 2026. Current price is above RBC's target.
Price and catalyst sequence
price path, directionalcatalyst
Next 42 hours
Q2 results
First report as a public company
First report as a public company
Investor call
Backlog, revenue and capacity focus
Backlog, revenue and capacity focus
Radiant agreement
Binding supply of multiple metric tons of TRISO fuel through 2031 for Radiant's one-megawatt Kaleidos microreactors.
Contract value was not disclosed. Delivery timing depends on reactor deployment and fuel availability.
Risk monitor
- Backlog may not convert into profitable revenue.
- Customers must obtain enriched uranium, including HALEU.
- Advanced-reactor schedules and approvals can slip.
- At $13.70, upside to the $16 average target is about 16.8%.
Sources: Standard Nuclear investor relations and SEC filings; Reuters; Yahoo Finance market data; S&P Global analyst data via Stock Analysis. Market figures timestamped Aug. 25, 2026, 15:10 EDT. Historical financials are through Mar. 31, 2026.
CryptocurrencyNASDAQ:ASST
Strive Shares Climb 9% After $81.5 Million Bitcoin Purchase Faces Dilution Challenge
Shares of Strive, Inc. rose 9.43% on Tuesday following the bitcoin-treasury firm’s announcement of its biggest weekly acquisition in several months. The stock changed…
NASDAQ: ASST · Bitcoin treasury
Strive’s 5.5% Bitcoin gain became 1.2% per share
The latest purchase expanded the treasury faster than common shares, but preferred issuance raised the senior capital claim.
U.S. regular session
ASST price
$21.59
+9.43% · August 25, 13:46 EDT
Volume
9.32M
2.10× 4.44M recent average
Bitcoin held
21,356
+1,110 in the latest week
Bitcoin / share
0.0002381
+1.19% week over week
Treasury growth versus the denominator
Bitcoin heldEffective common shares
Lines are indexed for visual comparison; data labels show reported values. Effective shares combine Class A and Class B.
Latest filing: August 14 → August 21
Bitcoin20,246 → 21,356 +5.48%
Effective common shares86.04M → 89.68M +4.24%
Fully diluted, before warrants89.30M → 92.95M
Traditional warrant shares26.60M
SATA preferred shares7.83M → 8.27M +5.64%
Cash$154.8M → $171.9M
The treasury grew faster than the common-share count. That made the weekly transaction modestly accretive on Strive’s preferred metric.
Common-equity value bridge
Estimate at Bitcoin $78,646, August 25, 13:46 EDT. Gross liquid assets include 21,356 BTC, $171.9M cash and $48.6M STRC. SATA claim assumes $100 liquidation preference. It excludes operating value, taxes, other liabilities and warrant dilution.
Fundamentals and capital cost
| Q2 revenue | $2.9M |
| H1 revenue | $5.7M |
| H1 GAAP net loss | $523.5M |
| H1 preferred dividends | $39.7M |
| H1 operating cash flow | -$39.4M |
| SATA annualized dividend rate | 13.0% |
| Short- and long-term debt | $0 by Aug. 7 |
GAAP losses were dominated by bitcoin and preferred-security revaluation. The dividend burden is a recurring cash claim.
Verified analyst recommendations
| Firm | Date | Action | Rating | Target | Upside / downside vs $21.59 |
|---|---|---|---|---|---|
| H.C. Wainwright | Aug. 11 | Maintained; target cut | Buy | $36 | +66.7% |
| TD Cowen | Jul. 22 | Maintained; target cut | Buy | $28 | +29.7% |
| Benchmark | Jun. 2 | Initiated | Buy | $32 | +48.2% |
| B. Riley | May 15 | Maintained | Buy | $20 | -7.4% |
| S&P Global consensus | Current | Five analysts | Strong Buy | $26.60 | +23.2% |
What moves the next print
Bitcoin sensitivityEach $1,000 BTC move changes gross treasury value by about $21.4 million before tax and other claims.
Issuance efficiencyWatch whether bitcoin-per-share growth stays positive as common and SATA programs remain active.
Preferred coverageAt 8.27 million SATA shares and a 13% rate, the annualized dividend burden is roughly $107.5 million.
Sources: Strive August 24 Form 8-K; Strive Q2 Form 10-Q; Yahoo Finance; Reuters; Benzinga analyst history. TS2 calculations use reported figures and the August 25 market snapshot.
NASDAQ:RUMSemiconductors
RUM Group Shares Climb 12% Following $13.7 Billion GPU Agreement Featuring 50.8 Million-Share Warrant
NEW YORK, August 25, 2026, 13:27 EDT — RUM Group stock advanced 12% after the company disclosed a $13.7 billion GPU transaction, which includes…
RUM Group · NASDAQ: RUM
$13.7B order meets a financing test
GPU-services contract, customer warrant and execution dashboard
Market snapshot
Aug. 25, 2026 · 13:27 EDT
U.S. regular session open
Aug. 25, 2026 · 13:27 EDT
U.S. regular session open
Share price
$10.48
+$1.12 · +11.97%
Session volume
5.21M
Intraday · CBOE/UTP feed
Market value
$4.19B
About 35.6× trailing sales
Session range
$9.23–$10.57
New 52-week high
Seven-session price path
Closes: $8.24, $8.10, $8.32, $8.43, $9.05, $9.36; Aug. 25 intraday: $10.48.
Contract scale
Annualized contract value is 6.3× annualized Q3 guidance. Recognition timing is not disclosed.
Capital and dilution
| Cash and equivalents | $203.3M | June 30 |
| Total liquidity | $220.5M | June 30 |
| Convertible note payable | $358.8M | June 30 |
| Customer warrant | 50.81M | $0.01 strike |
| Warrant / economic shares | 12.7% | Class A+C base |
Operating baseline
| Q2 revenue | $40.4M | +61% YoY |
| Northern Data contribution | $10.1M | Post-close period |
| Q2 net loss | -$80.3M | GAAP |
| Adjusted EBITDA | -$16.6M | vs. -$20.5M |
| Existing GPU utilization | ~85% | Q2 |
What has to happen
Aug. 23
Agreement signed
Three purchase tranches over six years; third tranche requires delivery-date approval.
Three purchase tranches over six years; third tranche requires delivery-date approval.
Next
Financing package
RUM says it lacks the required funding and expects debt and/or equity.
RUM says it lacks the required funding and expects debt and/or equity.
Buildout
Maysville delivery
Data center, power, GPUs, networking and related equipment must be procured and commissioned.
Data center, power, GPUs, networking and related equipment must be procured and commissioned.
Milestones
Revenue and warrant vesting
Initial warrant half vests with original purchases; the balance needs expansion deals.
Initial warrant half vests with original purchases; the balance needs expansion deals.
Analyst snapshot
| Firm | Rating | Target |
|---|---|---|
| Maxim Group Aug. 19 | Buy | $22 |
| Oppenheimer Aug. 17 | Hold | — |
Two tracked analysts; consensus Hold. Coverage is too narrow for a robust distribution.
Signals for investors
| Positive | $13.7B anchor order; 85% utilization on the existing GPU estate; a new 52-week stock high. |
| Unresolved | Customer identity, delivery calendar, financing terms, capex budget and revenue recognition. |
| Downside | Near-zero-strike warrant, further equity dilution, added leverage, construction delays and contractual remedies. |
Valuation lens
| Trailing revenue | $117.7M |
| Current market cap / sales | 35.6× |
| 2026 revenue consensus | $243.7M |
| 2027 revenue consensus | $559.0M |
| Average target / current | $22 / $10.48 |
Forward figures are analyst estimates, not company guidance.
Sources: RUM Form 8-K; Q2 Form 10-Q; Q2 results; StockAnalysis market data; analyst estimates; Reuters.
BiotechnologyNASDAQ:CRSP
CRISPR Therapeutics Shares Advance 5.8% Ahead of CTX310 Results Release
Shares of CRISPR Therapeutics AG rose 5.8% on Tuesday, increasing its market capitalisation by roughly $319 million ahead of new CTX310 clinical results.
NASDAQ: CRSP · Stock move
CRISPR Therapeutics
CTX310 durability data becomes the next valuation test
Market data: Aug. 25, 2026, 12:38:56 EDT
U.S. regular session · Prices intraday
U.S. regular session · Prices intraday
Share price
$60.38
▲ $3.30 · +5.79%
Market cap
$5.84B
96.69M shares outstanding
Value added today
≈$319M
$3.30 × 96.69M shares
Citizens target
$80
+32.5% · ≈$7.74B implied cap
Intraday range and reference levels
The $80 target sits above the displayed 52-week high. Levels as of 12:38:56 EDT.
Balance-sheet and earnings frame
| Cash + marketable securities | $2.364B |
| Cash as share of market cap | 40.5% |
| Q2 revenue | $10.2M |
| Q2 R&D expense | $67.2M |
| Q2 net loss | $91.2M |
| CASGEVY Q2 global revenue | $76M |
Company data for quarter ended June 30, 2026; CASGEVY revenue is global product revenue reported by CRISPR.
Analyst map
| Firm | Latest action | Rating | Target | Implied return |
|---|---|---|---|---|
| Citizens | Aug. 25 | Market Outperform | $80 | +32.5% |
| Goldman Sachs | Aug. 10 | Hold | $55 | −8.9% |
| Bank of America | Aug. 5 | Buy | $82 | +35.8% |
| Morgan Stanley | Aug. 4 | Hold | $60 | −0.6% |
| Piper Sandler | Aug. 4 | Buy | $110 | +82.2% |
Google Finance displayed 13 analysts: eight Buy, five Hold and no Sell; average target $74.33. Implied returns use $60.38.
Catalyst clock
Aug. 25 · 12:38:56 EDTCRSP +5.79%; intraday high $61.55.
Aug. 28 · 16:30 CEST · MunichLate-breaking ESC presentation: durability of CTX310 effects.
Second half 2026Broader Phase 1b CTX310 update expected.
What the price is discounting
A durable ANGPTL3 response could add an in-vivo cardiovascular franchise beside CASGEVY. Tuesday's move capitalized that possibility before the data.
Risk check
CTX310 is early-stage. Small cohorts, safety findings or weaker durability could erase the move. Clinical value remains distinct from commercial value.
Investor bridge
$319 million gained versus $2.364 billion of liquidity. The stock's one-day market-value increase equals roughly 13.5% of reported cash and securities. Citizens' $80 target adds another $1.90 billion of implied equity value from the midday base. The August 28 data therefore tests whether investors will assign meaningful value to CTX310 before later-stage evidence.
Sources: CRISPR Therapeutics Q2 2026 business update; Google Finance; Citizens research note reported by Investing.com. Calculations may differ slightly because market capitalization and shares outstanding are rounded.
NASDAQ:MRNAPharmaceuticals
Moderna Stock Jumps 12% as Wolfe Sees $9.2 Billion Intismeran Opportunity
Moderna shares jumped 12.2% on Tuesday after Wolfe Research abandoned its bearish rating. The move extended a volatile repricing of the vaccine maker's cancer…
NASDAQ: MRNA · STOCK MOVE
Moderna's oncology re-rating
Market snapshot: August 25, 2026, 11:25 EDT · U.S. regular session
+12.18% today
Share price
$155.81
Day range $141.21–$159.20
Trading volume
23.8M
1.80× 3-month daily average
Market value
$62.2B
399.2M shares outstanding
52-week position
88%
$22.28 low · $176.66 high
Session performance: company-specific buying
Prices from Yahoo Finance, captured August 25, 2026, 11:25 EDT.
Analyst targets versus $155.81
UBS
Neutral
$150Barclays
Equal Weight
$125Goldman
Neutral
$120Morgan Stanley
Equal Weight
$89JPMorgan
Underweight
$7723-analyst consensus$95.67 · Hold
S&P Global analyst snapshot, accessed August 25, 2026.
Balance-sheet bridge
Q2 revenue$145M · +2% YoY
Q2 net loss-$782M
Q2 R&D expense$651M · -7% YoY
June 30 cash + investments$6.9B
2026 revenue goalUp to +10%
Year-end cash guide$4.7B–$5.2B
Moderna Q2 2026 results, July 31, 2026.
Catalyst path
Aug. 19INTerpath-001 met its primary and key secondary endpoints. Detailed efficacy data remain pending.
Aug. 24Barclays lifted its target to $125 from $48 and kept Equal Weight.
Aug. 25Wolfe moved to Peer Perform and introduced a $9.2B four-indication peak-sales marker.
Next proofFull Phase 3 data, regulatory discussions, launch timing and personalized-manufacturing economics.
Stock Market
Kura Oncology Shares Surge 9% Following CEO’s $2.35 Million Purchase Over Eight Days
Kura Oncology, Inc. surged 8.87% on Tuesday following a second significant open-market buy from its CEO. The stock was last at $13.50 as of…
NASDAQ: KURA · Company · Stock move
Kura Oncology: a $2.35 million insider-confidence test
Market open snapshot
August 25, 2026 · 10:25 EDT / 16:25 CEST
August 25, 2026 · 10:25 EDT / 16:25 CEST
Share price
$13.50
▲ 8.87% vs. $12.40 prior close
Volume
1.89M
Through 10:25 EDT; recent full-day average ≈2.70M
Market value
$1.20B
88.96M shares outstanding
Intraday range
$12.85–13.73
Open $13.59; new 52-week high
Price path and the two CEO purchases
Daily close / live priceCEO open-market buy
Insider math
Shares bought200,000
Total cost$2.351M
Blended price$11.755
Value at $13.50$2.700M
Paper gain$349K / 14.8%
Disclosed position1,214,650 shares
SEC Forms 4 filed August 17 and August 24, 2026. The latest purchase ranged from $11.47 to $12.85.
The commercial engine
Q2 product revenue$9.1M
New patient starts≈115
Total prescriptions>250
Cash + investments$519.0M
Analyst target map
ConsensusStrong Buy
Analysts15
Average-target upside137%
Targets are opinions, not forecasts of realized value. Consensus data checked August 25, 2026.
Investor bridge
The insider purchase matters because it follows measurable launch traction. KOMZIFTI is growing quickly, but $9.1 million of quarterly product sales remains far below $93.9 million of operating expenses. The stock now asks investors to price faster adoption, a $519 million cash cushion and multiple clinical readouts against continued losses.
Risks
Insider buying can be wrong. Prescription growth may slow. Trial results can fail, and a long development path may require capital despite the stated runway through the first pivotal Phase 3 readout in 2028.
Sources and timing
SEC Forms 4 (Aug. 17 and Aug. 24, 2026); Kura Oncology Q2 release (Aug. 12, 2026); S&P Global/StockAnalysis analyst and tape data. Every market figure is timestamped August 25, 2026, 10:25 EDT / 16:25 CEST.
SafetyStock Market
Montreal-Trudeau Death Brings Ground-Handling Safety to Fore for Investors
An apron accident at Montréal-Trudeau airport has highlighted concerns over ground-handling safety. ADM Aéroports de Montréal on Tuesday confirmed the Samsic worker involved has…
Market / Asset / Sector · Aviation operations
montreal trudeau airport
A fatal pushback accident was followed by a route-specific delay, not a network shutdown. The investor test is whether the inquiry finds a local procedural failure or a wider ground-handling control gap.
Data cutoffAugust 25, 2026
09:24 EDT · 15:24 CEST
Toronto equities: pre-open
09:24 EDT · 15:24 CEST
Toronto equities: pre-open
Human outcome
Fatal
ADM confirmed the Samsic employee’s death at 09:12 EDT.
Flight delay
6h 09m
18:00 scheduled departure; 00:09 recorded departure.
Airport status
Operating
ADM said wider YUL operations continued after the event.
YUL 2025 traffic
22.4m
Passengers, down 0.5% from 2024.
Verified event clock · EDT
Known: a French Bee A350 was involved during pushback. Not established: fault, a technical defect, or whether the later aircraft carried the original passengers.
Operating scale and safety tail risk
+2.4%YUL international traffic, 2025
−9.5%YUL transborder traffic, 2025
Transmission map
| Exposure | Link | Current reading |
|---|---|---|
| French Bee | Flight operator · private | Direct Route delay; cooperating with authorities |
| Samsic | Worker’s employer · private | Direct Workplace inquiry is central |
| ADM | YUL operator · not-for-profit | Operational Airport remained open |
| Air Canada (TSE:AC) | Largest listed YUL airline exposure | Not involved Network impact only if disruption broadens |
| Airbus SE (EPA:AIR) | A350 manufacturer | No finding No technical defect identified |
Investor watchlist
- Investigation owner: CNESST workplace case; TSB was notified.
- Control failure: marshalling, pushback procedure, staffing or equipment.
- Remediation: training pause, stand restrictions or new ramp controls.
- Cost path: handler liability, insurance renewal and contract indemnities.
- Capacity test: whether YUL’s growth plan changes apron investment priorities.
Market read: Canadian equities were pre-open at the 09:24 EDT cutoff. There was no incident-day price signal to attribute.
Sources: ADM update via PAX · AeroTime flight-record review · The Canadian Press via Global News · IATA ground-operations data · ADM 2025 results · ADM Flight Plan 2028–2035. Figures are preliminary where investigations remain open.
Stock MarketTechnology
Australian equity market closed as A$13 million response to remote diphtheria outbreak tested
SYDNEY, August 25, 2026, 20:45 AEST — The Australian cash equity market has closed for the day as the country continues to roll out…
Australia diphtheria: the infrastructure test
Updated 25 August 2026, 20:45 AEST · ASX cash market closed · Data are notifications and may be revised
538
2026 cases reported by 25 Aug
17.4×
versus 2022 annual peak of 31
A$13m
federal response package
~A$24.2k
response budget per notified case*
Outbreak trajectory
Cumulative notified casesLatest fortnight: 26, versus almost 80 at peak
Where the burden sits
| Jurisdiction | Cases to 10 Aug | Share |
|---|---|---|
| Northern Territory | 274 | 53.4% |
| Western Australia | 217 | 42.3% |
| South Australia | 17 | 3.3% |
| Queensland | 5 | 1.0% |
18.5%
hospitalised: 95 of 513 to 10 Aug
95.5%
Aboriginal and/or Torres Strait Islander cases
99.0%
locally acquired cases outside major cities
A$4bn
10-year NT remote-housing commitment
Policy scoreboard
| 22 May | Incident declared nationally significant; more than 230 cases. |
|---|---|
| 10 Aug | 513 cases; 28 notifications in prior fortnight, down from 35. |
| 25 Aug | 538 cases; response package raised to A$13m. |
| Next | Fortnightly CDC reports; booster uptake; remote-housing delivery. |
Investor transmission
ImmediateVaccines, antibiotics, surge staffing, diagnostics and cold-chain logistics.
BudgetSmall national outlay, but concentrated operating pressure in remote jurisdictions.
StructuralHousing, water and sanitation determine whether emergency spending must persist.
Listed exposureDiffuse sector demand; no single stock is a clean proxy for the outbreak.
Scenario frame — next 4–8 weeks
| Scenario | Signal | Market implication |
|---|---|---|
| Base | Fortnightly cases keep declining; testing stable | Surge spending plateaus; logistics pressure eases |
| Upside | Booster uptake rises; no new geographic spread | Lower health-system utilization and procurement urgency |
| Downside | Testing reveals hidden spread or housing delays persist | Longer staffing, transport and treatment commitments |
What matters most
The A$13m package is tactical. The A$4bn remote-housing commitment is structural and about 308 times larger. Execution, not headline vaccination coverage, is the key long-duration variable.
Risk: Recent declines may be overstated because testing and notification lag. Hospitalisation also reflects infection-control practice, not disease severity alone.
*A$13m divided by 538 notifications; this is not a treatment-cost estimate. Sources: Australian CDC epidemiological update dated 10 August 2026; Australian CDC disease page; ABC News report updated 25 August 2026 at 11:23 AEST; Australian Government remote-housing announcement; ASX cash-market hours. Scenario labels are analytical, not government forecasts.
Stock Market
Trump Weighs $366 Million Visa Revocation Ceiling as Premarket U.S. Stock Trading Begins
The Trump administration plan to revoke a large number of visas features an eye-catching headline figure, but the actual impact on travel is much…
U.S. visa policy · macro transmission
200,000 revocations: large headline, narrow first-order shock
The proposed ceiling targets B1/B2 holders who later sought asylum. The direct count is small against U.S. inbound travel, but policy spillover could alter bookings before the 2026 World Cup.
Data cut: Aug. 25, 2026
10:02 CEST / 04:02 EDT
U.S. premarket newly open
10:02 CEST / 04:02 EDT
U.S. premarket newly open
Reported ceiling
200,000
B1/B2 holders linked to asylum claims; final count dynamic.
Share of 2026 arrivals
0.28%
Against NTTO's 70.5 million official forecast.
Gross spend ceiling
$366M
One lost trip per visa × $1,829 average; not a forecast.
2025 travel exports
$250.2B
International visitor spending, down 0.6% year over year.
Illustrative direct exposure — not a forecast
Method: one hypothetical lost future visit per revoked visa × NTTO's $1,829 average 2025 U.S. spend by an overseas visitor. Many affected people are already in the U.S.; actual lost inbound trips may be much lower.
Scale check
| Baseline | Reading | Signal |
|---|---|---|
| 2025 arrivals | 68.3M | Actual |
| 2026 arrivals | 70.5M | +3.2% forecast |
| March 2026 | 5.54M | +2.0% YoY |
| 200K cohort | ~1 day | At 2026 run-rate |
| Prior revocations | 175K | Past 18 months |
Policy timeline
2016–2026Issuance window for B1/B2 visas under review.
Past 18 monthsAbout 175,000 visas revoked on multiple stated grounds.
Aug. 22Judge strikes down a separate 75-country immigrant-visa freeze.
Aug. 24Up-to-200,000 asylum-linked plan reported after market close.
Coming weeksState Department expected to publish implementation details.
Sector sensitivity
| Channel | First-order exposure | Investor metric |
|---|---|---|
| Online travel agencies | Cross-border booking conversion | U.S. inbound room nights |
| Gateway hotels | International occupancy and ADR | New York, Miami, Los Angeles RevPAR |
| International airlines | Visitor-origin load factors | Advance bookings and yields |
| Airports / concessions | Passenger and retail spend | International enplanements |
| Domestic leisure | Lower direct sensitivity | Drive-to demand |
Transmission map
ScopeAsylum-linked cohort only.
SignalPerceived entry uncertainty.
BehaviorSearches and bookings soften.
MarketOTAs, hotels, airlines reprice.
Key asymmetry: direct arithmetic is small; an expansion to ordinary visitors would make the signaling channel much larger.
Investor conclusion
The proposed ceiling is only 0.28% of forecast 2026 arrivals, and the affected population does not map one-for-one to future trips. The near-term market test is therefore confidence. Watch the formal notice, country mix, court challenges, inbound searches and cancellation rates before treating 200,000 as an earnings input.
Sources: Reuters, Aug. 24; Associated Press; NTTO forecast; NTTO visitor survey; NTTO spending; NTTO March arrivals. Calculations use displayed government baselines and are illustrative.
CommoditiesStock Market
U.S. Cattle Futures Slide on Trump Beef Import Proposal, but Tight Supply Curbs Downside
U.S. cattle futures fell on Monday following President Donald Trump’s proposal for a 90-day, tariff-free import period for 300,000 metric tons of ground beef…
U.S. Beef Policy Dashboard
Trump's 90-day beef import plan
The quota looks large beside annual imports, but small beside total consumption. Futures are pricing the producer shock first.
Data through August 24, 2026
17:34 EDT / 23:34 CEST
U.S. livestock session closed
17:34 EDT / 23:34 CEST
U.S. livestock session closed
300k
metric tons, tariff-free over 90 days
10.9%
of USDA's projected 2026 beef imports
≈3%
of annual U.S. beef consumption
−1.97%
October live cattle, Aug. 24 session
One quota, three very different denominators
Investor read: The quota is meaningful for import competition and cattle prices. It is too small to produce a matching nationwide retail-price cut.
Bar lengths use separate scales to keep categories legible. Ratios: quota/imports 10.9%; quota/production 2.6%. USDA forecasts; calculated.
Monday's market verdict
| Contract | Close | Day |
|---|---|---|
| Oct live cattle | 213.62¢/lb | −1.97% |
| Sep feeder cattle | 324.15¢/lb | −1.48% |
August 24, 2026 settlements. Change calculated from August 21 closes.
Retail pressure remains hot
Year-over-year CPI, July 2026, U.S. Bureau of Labor Statistics. Ground beef averaged about $7.14/lb.
Tight herd keeps the floor firm
| Indicator | Latest | Signal |
|---|---|---|
| Beef cows | 28.5m head | −1% YoY |
| 2026 calf crop | 32.5m head | −2% YoY |
| 2026 production | 24.967bn lb | Forecast |
| 2027 availability | 59.2 lb/person | −1.3% |
USDA NASS and ERS, latest releases available August 24, 2026.
Policy path
Feb. 6
White House creates an 80,000-tonne annual quota for Argentine lean-beef trimmings.
Aug. 21
Trump announces a 300,000-tonne, 90-day tariff-free import proposal.
Aug. 24
Cattle futures fall; producer groups intensify opposition.
By Sep. 4*
Executive order expected within two weeks. Supplier countries and mechanics remain undisclosed.
*Indicative deadline based on the stated two-week window, not a confirmed date.
Who feels it first?
RanchersLower cattle bids; herd rebuilding may slow.
ProcessorsPotentially cheaper inputs; retail pass-through can narrow gains.
ConsumersSome relief, likely modest at national scale.
InflationDirectionally lower; weight in broad CPI is limited.
Sources: USDA NASS and ERS, U.S. Bureau of Labor Statistics, White House, Associated Press and August 24 livestock settlements. Policy details remain preliminary.
Stock Market
Tokyo Markets Braced as Earthquake Near Capital Challenges $150 Billion Tail Risk
TOKYO, August 25, 2026, 05:42 JST — Cash markets in Tokyo remained shut before Tuesday’s session, while the most recent official Osaka futures figures…
Japan earthquakes Tokyo
A contained M5.9 disruption meets a much larger Tokyo insurance tail risk.
Snapshot: 25 Aug 2026, 05:42 JST • Tokyo cash market closed; latest futures 24 Aug, 22:00 JST
JMA magnitude
5.9
23 Aug, about 02:00 JST
Reported injuries
37+
AP tally, 24 Aug
Nikkei 225
−0.74%
65,528.09 • 24 Aug close
TOPIX
+0.15%
4,073.29 • 24 Aug close
Market signal: index split, not broad flight
841 Prime shares rose658 fell51 unchanged
Interpretation: semiconductor-heavy Nikkei weakness contrasted with positive broad-market breadth. Reports pointed to chip positioning and higher yields, not earthquake liquidation.
Event facts
| Epicentre | Southern Ibaraki |
| Depth | ~70 km |
| Max intensity | Lower 5, JMA scale |
| Tsunami | None |
| Nuclear anomalies | None reported |
| Aftershock window | About one week |
Transmission channels
| Channel | Current reading | Sensitivity |
|---|---|---|
| Transport | Brief rail delays; Shinkansen normal | |
| Utilities | Local outages; one Tokyo pipe repaired | |
| Industrial supply | No broad shutdowns reported | |
| Insurance | Claims likely local; tail exposure high | |
| Financial plumbing | BoJ backup plans rehearsed |
Sensitivity bars are qualitative risk channels, not loss forecasts.
Timeline to watch
23 Aug • about 02:00 JSTM5.9 quake; rail, power and water disruptions reported.
24 Aug • 15:00 JSTNikkei −0.74%; TOPIX +0.15%; positive Prime breadth.
24 Aug • 22:00 JSTNikkei futures 65,510, just 18.09 points below cash.
Through about 30 AugJMA warning window for similar shaking remains active.
Magnitude comparison
Calculated with the standard magnitude-energy relationship: 101.5×(7.1−5.9). This is a physical comparison, not a damage estimate.
Tail-risk scale
$130–150bn
Swiss Re's insured-loss scenario for a severe Tokyo-region earthquake. It is not an estimate for the current M5.9 event.
The current market calm reflects limited observed damage. It does not remove Tokyo's concentration risk.
Tuesday decision map
| Signal | Contained case | Escalation case |
|---|---|---|
| Aftershocks | No stronger event | Similar or stronger shaking |
| Infrastructure | Services normalized | New rail, utility or data-centre outages |
| Equities | TOPIX breadth stays positive | Broad selling replaces index-only weakness |
| Credit/insurance | Local claims | Material loss disclosures or reserve changes |
Sources
AP event report
Kabutan close
OSE futures snapshot
Swiss Re scenario
BoJ continuity planning
CommoditiesNYSE:NEM
Gold Reaches Three-Month Peak; Newmont Shares Fall as Rising Costs Limit Gains
Gold climbed to its highest level in three months on Monday, supported by a softer dollar and renewed Treasury buybacks. The gains lifted bullion…
Newmont Corporation · NYSE:NEM
Gold broke higher.
Newmont did not.
Bullion reached a three-month high, but the miner slipped as investors weighed rising mine costs, a recent share-price run and limited upside to the average analyst target.
Market snapshot
$131.04
−0.40% · −$0.52
August 24, 2026 · 14:46 EDT
U.S. regular session · USD
Gold spot$4,639.49per oz · +0.8% at 14:25 EDT
NEM day range$129.17–133.64high faded into afternoon
Market value$139.8Blargest listed gold miner
Forward signal$136.58average analyst target · +4.2%
Gold's four-session breakout
The latest move followed Treasury buyback support, a weaker dollar and the strongest gold-ETF inflow in 10 months.
Why NEM moved down
| Pressure | Evidence |
|---|---|
| Profit-taking | Shares reversed from $133.64 after a 31.5% YTD return. |
| Cost drag | Q2 by-product AISC rose 58% q/q to $1,621/oz. |
| Valuation | Average target leaves only 4.2% upside. |
| No fresh company catalyst | Monday's move was metal-led, not earnings-led. |
Operating leverage
| Measure | Value | Read-through |
|---|---|---|
| Q2 realized gold | $4,414/oz | Monday spot +$225 |
| Q2 by-product AISC | $1,621/oz | Wide margin, but costs rose |
| Q2 free cash flow | $2.2B | Record second quarter |
| 2026 production guide | 5.3Moz | Reaffirmed |
Analyst positioning
Google Finance: 11 Buy · 1 Hold · 0 Sell
| Target | Price | Vs. $131.04 |
|---|---|---|
| High | $170.00 | +29.7% |
| Average | $136.58 | +4.2% |
| Low | $110.00 | −16.1% |
Sources: Reuters gold-market report, Google Finance, Newmont Q2 2026 results, World Gold Council. Market prices are time-sensitive and carry the timestamps shown. AISC and free cash flow are company-defined non-GAAP measures. This dashboard is informational, not investment advice.